SCHEMBL2137684

SCHEMBL2137684

NNc1nc2cc(Cl)ccc2s1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 1.00
MEN1 O00255 6/20 0.75
KMT2A Q03164 6/20 0.75
LMNA P02545 5/20 0.75
MAPT P10636 5/20 0.75
GAA P10253 5/20 0.75
NPC1 O15118 4/20 0.75
RAB9A P51151 4/20 0.75
SMN1; SMN2 Q16637 3/20 0.75
ALDH1A1 P00352 3/20 0.75
KDM4E B2RXH2 3/20 0.75
ALOX12 P18054 2/20 0.75
HTT P42858 1/20 0.75
LOXL2 Q9Y4K0 1/20 0.56
TDP1 Q9NUW8 3/20 0.51
PKM P14618 2/20 0.51
MAPK1 P28482 2/20 0.51
POLB P06746 2/20 0.51
NPSR1 Q6W5P4 1/20 0.51
GFER P55789 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2116067 0.86 MEN1 (1.00) IDO1MEN1KMT2ALMNAMAPT
SCHEMBL29858587 0.82 IDO1 (0.70) IDO1MEN1KMT2ALMNAMAPT
SCHEMBL3408807 0.82 IDO1 (0.70) IDO1MEN1KMT2ALMNAMAPT
SCHEMBL11216268 0.80 IDO1 (0.67) IDO1MEN1KMT2ALMNAMAPT
SCHEMBL22833881 0.79 MAPT (0.75) IDO1MEN1KMT2ALMNAMAPT
SCHEMBL29379319 0.79 MAPT (0.75) IDO1MEN1KMT2ALMNAMAPT
SCHEMBL2138878 0.79 IDO1 (0.65) IDO1MEN1KMT2ALMNAMAPT
SCHEMBL13284915 0.78 IDO1 (0.64) IDO1MEN1KMT2ALMNAMAPT
SCHEMBL8122841 0.77 SMN1; SMN2 (0.66) IDO1MEN1KMT2ALMNAMAPT
SCHEMBL780242 0.77 SMN1; SMN2 (0.61) IDO1MEN1KMT2ALMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230278984-A1 UREA DERIVATIVES AS PYRUVATE KINASE ACTIVATORS GLOBAL BLOOD THERAPEUTICS INC (US) 2023-09-07 US disclosed
EP-4188542-A1 UREA DERIVATIVES AS PYRUVATE KINASE ACTIVATORS Global Blood Therapeutics, Inc. (US) 2023-06-07 EP disclosed
WO-2022031735-A1 UREA DERIVATIVES AS PYRUVATE KINASE ACTIVATORS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2022-02-10 WO disclosed
EP-2822945-B1 AMINOMETHYLENE PYRAZOLONES WITH THERAPEUTIC ACTIVITY COMPOUND HANDLING B V (NL) 2019-06-19 EP disclosed
US-10071987-B2 Aminomethylene pyrazolones with therapeutic activity COMPOUND HANDLING B.V. (NL) 2018-09-11 US disclosed
US-20180030035-A1 AMINOMETHYLENE PYRAZOLONES WITH THERAPEUTIC ACTIVITY COMPOUND HANDLING B.V. (NL) 2018-02-01 US disclosed
US-9790205-B2 Aminomethylene pyrazolones with therapeutic activity COMPOUND HANDLING B.V. (NL) 2017-10-17 US disclosed
US-20170240531-A1 AMINOMETHYLENE PYRAZOLONES WITH THERAPEUTIC ACTIVITY COMPOUND HANDLING B.V. (NL) 2017-08-24 US disclosed
US-9676764-B2 Aminomethylene pyrazolones with therapeutic activity COMPOUND HANDLING B.V. (NL) 2017-06-13 US disclosed
US-20160326152-A1 AMINOMETHYLENE PYRAZOLONES WITH THERAPEUTIC ACTIVITY COMPOUND HANDLING B.V. (NL) 2016-11-10 US disclosed
WO-2012006068-A2 COMPOUNDS FOR THE INHIBITION OF CELLULAR PROLIFERATION PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2012-01-12 WO disclosed
EP-1473286-B1 PROCESS FOR PRODUCING BIARYL COMPOUND SUMITOMO CHEMICAL CO (JP) 2009-11-04 EP disclosed
US-20090216017-A1 PROCESS FOR PRODUCING BIARYL COMPOUND HAGIYA KOJI 2009-08-27 US disclosed
US-7554000-B2 Process for producing biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-06-30 US disclosed
CN-1303043-C Process for producing biaryl compound SUMITOMO CHEMICAL CO (JP) 2007-03-07 CN disclosed
CN-1642879-A Process for preparing diaryl compounds SUMITOMO CHEMICAL CO (JP) 2005-07-20 CN disclosed
US-20050096471-A1 Process for producing biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2005-05-05 US disclosed
EP-1473286-A1 PROCESS FOR PRODUCING BIARYL COMPOUND Sumitomo Chemical Company, Limited (JP) 2004-11-03 EP disclosed
US-4732986-A Benzothiazole derivatives, processes for their preparation and pharmaceutical compositions containing these compounds LUDWIG HEUMANN & CO. GMBH (DE) 1988-03-22 US disclosed
EP-0160173-A1 Benzothiazole derivatives, processes for their production and medicaments containing them LUDWIG HEUMANN & CO GMBH (DE) 1985-11-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180030035-A1 AMINOMETHYLENE PYRAZOLONES WITH THERAPEUTIC ACTIVITY H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NCOA3, CBR3 IDO1 1387/4885MEN1 3623/4885KMT2A 2650/4885
US-20090216017-A1 PROCESS FOR PRODUCING BIARYL COMPOUND PPOX, CAT, TYR IDO1 233/4885MEN1 3325/4885KMT2A 575/4885
US-20230278984-A1 UREA DERIVATIVES AS PYRUVATE KINASE ACTIVATORS PKM, PDK1, PDK2 IDO1 4037/4885MEN1 4531/4885KMT2A 1249/4885
US-10071987-B2 Aminomethylene pyrazolones with therapeutic activity H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NCOA3, CBR3 IDO1 1387/4885MEN1 3623/4885KMT2A 2650/4885
US-20170240531-A1 AMINOMETHYLENE PYRAZOLONES WITH THERAPEUTIC ACTIVITY H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NCOA3, CBR3 IDO1 1457/4885MEN1 3872/4885KMT2A 2695/4885
US-20160326152-A1 AMINOMETHYLENE PYRAZOLONES WITH THERAPEUTIC ACTIVITY H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NCOA3, CBR3 IDO1 1457/4885MEN1 3872/4885KMT2A 2695/4885
US-20050096471-A1 Process for producing biaryl compound PPOX, CAT, TYR IDO1 233/4885MEN1 3325/4885KMT2A 575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.